Company Overview and News

1
Shanghai’s answer to Manhattan in the making

2018-06-05 scmp
More than half of the 1.65m sq m of Pudong’s new office supply in the next five years will come from Qiantan, Shanghai’s second financial district south of the core Lujiazui area
SHTGF 1972 SHTGY SWROY RAFLF R01 RAFLY SWPFF UTX 0242

 
Group led by Hong Kong conglomerate New World Development wins Singapore plot for US$306.76 million

2018-05-17 scmp
Hong Kong conglomerate New World Development is part of a consortium that has won the tender for a luxury residential site close to Orchard Road, Singapore’s famous shopping and entertainment strip, securing the plot for S$2,377 per square foot, a record for all government residential sites in the city.
SUHJY 0017 0016 SHTGF WTHEF SHGKF SHTGY B61 SHGKY 0086 0242 SUHJF

 
Macau casino magnate Stanley Ho, 96, to retire

2018-04-13 themalaymailonline
A taxi in which the Casino Lisboa is reflected stops in front of the Grand Lisboa, in Macau owned by tycoon Stanley Ho, February 25, 2015. — Reuters picHONG KONG, April 13 — Macau gambling tycoon Stanley Ho will step down from his flagship casino empire SJM Holdings, the company said late yesterday, as the 96-year-old magnate hands over the reins to his daughter.
SHTGF SHTGY SJMHF 0880 0242 SJMHY

 
Macau casino magnate Stanley Ho to retire

2018-04-12 channelnewsasia
HONG KONG: Macau gambling tycoon Stanley Ho will step down from his flagship casino empire SJM Holdings, the company said late on Thursday (Apr 12), as the 96-year-old magnate hands over the reins to his daughter.
SHTGF SHTGY SJMHF 0880 0242 SJMHY

 
Macau gambling tycoon Stanley Ho, 96, will retire as chairman of casino operator SJM Holdings

2018-04-12 scmp
Ho will stay on as chairman emeritus to the company; his daughter Daisy will take over the reins of the business
SHTGF SHTGY SJMHF 0880 0242 SJMHY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...